Broncus Medical-B (02216) Surges Over 12% Intraday as BroncAblate Pulmonary RF Ablation System Enters Commercialization

Stock News

Jul 16, 2025

Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's announcement that its BroncAblate pulmonary radiofrequency ablation system has officially commenced commercialization.

Earlier developments paved the way for this milestone: In April, Broncus secured approval for its disposable BroncAblate ablation catheter. Subsequently, June brought regulatory clearance from China's NMPA for the BroncAblate console. These approvals collectively enable the full commercial rollout of BroncAblate—the world’s first transbronchial radiofrequency ablation device for lung cancer treatment.

Huatai Securities highlighted Broncus’s expanding pipeline in a recent research note. The RF-II lung cancer therapy, having released pre-market clinical trial results in August 2024, is anticipated to launch domestically in 2025. Meanwhile, the TLD device targeting COPD treatment completed patient enrollment across 20+ hospitals by late 2024, with full follow-up expected by 2026. The transbronchial flexible surgical robot remains in preliminary research phases.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1136361203"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1136361203\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1136361203?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-16 15:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136361203","market":"sg","top_or_hot":-1,"title":"Broncus Medical-B (02216) Surges Over 12% Intraday as BroncAblate Pulmonary RF Ablation System Enters Commercialization","media":"Stock News","content":"<p>Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's announcement that its BroncAblate pulmonary radiofrequency ablation system has officially commenced commercialization.</p>\n<p>Earlier developments paved the way for this milestone: In April, Broncus secured approval for its disposable BroncAblate ablation catheter. Subsequently, June brought regulatory clearance from China's NMPA for the BroncAblate console. These approvals collectively enable the full commercial rollout of BroncAblate—the world’s first transbronchial radiofrequency ablation device for lung cancer treatment.</p>\n<p>Huatai Securities highlighted Broncus’s expanding pipeline in a recent research note. The RF-II lung cancer therapy, having released pre-market clinical trial results in August 2024, is anticipated to launch domestically in 2025. Meanwhile, the TLD device targeting COPD treatment completed patient enrollment across 20+ hospitals by late 2024, with full follow-up expected by 2026. The transbronchial flexible surgical robot remains in preliminary research phases.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Broncus Medical-B (02216) Surges Over 12% Intraday as BroncAblate Pulmonary RF Ablation System Enters Commercialization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBroncus Medical-B (02216) Surges Over 12% Intraday as BroncAblate Pulmonary RF Ablation System Enters Commercialization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-07-16 15:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's announcement that its BroncAblate pulmonary radiofrequency ablation system has officially commenced commercialization.</p>\n<p>Earlier developments paved the way for this milestone: In April, Broncus secured approval for its disposable BroncAblate ablation catheter. Subsequently, June brought regulatory clearance from China's NMPA for the BroncAblate console. These approvals collectively enable the full commercial rollout of BroncAblate—the world’s first transbronchial radiofrequency ablation device for lung cancer treatment.</p>\n<p>Huatai Securities highlighted Broncus’s expanding pipeline in a recent research note. The RF-II lung cancer therapy, having released pre-market clinical trial results in August 2024, is anticipated to launch domestically in 2025. Meanwhile, the TLD device targeting COPD treatment completed patient enrollment across 20+ hospitals by late 2024, with full follow-up expected by 2026. The transbronchial flexible surgical robot remains in preliminary research phases.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02216","symbol_name":"堃博医疗-B","start_time":0,"source_url":"","article_id":"1136361203","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136361203","pubTimestamp":1752651066,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02216":"堃博医疗-B","BK1100":"医疗保健设备"},"translate_title":"BroncAblate肺部射频消融系统进入商业化，Broncus Medical-B(02216)盘中大涨超12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02216":1},"content_text":"Broncus Medical-B (02216) witnessed an intraday surge exceeding 12%, trading at HK$2.29 by press time—an 11.17% increase—with turnover reaching HK$27.34 million. This momentum follows the company's announcement that its BroncAblate pulmonary radiofrequency ablation system has officially commenced commercialization.\nEarlier developments paved the way for this milestone: In April, Broncus secured approval for its disposable BroncAblate ablation catheter. Subsequently, June brought regulatory clearance from China's NMPA for the BroncAblate console. These approvals collectively enable the full commercial rollout of BroncAblate—the world’s first transbronchial radiofrequency ablation device for lung cancer treatment.\nHuatai Securities highlighted Broncus’s expanding pipeline in a recent research note. The RF-II lung cancer therapy, having released pre-market clinical trial results in August 2024, is anticipated to launch domestically in 2025. Meanwhile, the TLD device targeting COPD treatment completed patient enrollment across 20+ hospitals by late 2024, with full follow-up expected by 2026. The transbronchial flexible surgical robot remains in preliminary research phases.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}